Most Innovative Companies

T2 Biosystems

Sepsis kills more people every year than breast cancer, prostate cancer, and AIDS combined. T2, founded in 2006, builds diagnostic tests and tools that help detect sepsis-causing pathogens faster than ever, and start life-saving treatments in time to make a difference. T2’s first test, for rapidly diagnosing deadly strains of candida, was approved by the FDA in 2014. In May 2018, the agency cleared T2’s bacteria panel, which IDs 50% of all bacterial bloodstream infections, 70% of all blood-culture species in the emergency department, and 90% of deadly ESKAPE pathogens. Both tests run on the T2DX Instrument, an automated desktop lab that returns results within 3 to 5 hours, versus 1 to 5 days for existing tests, which require waiting for a blood culture. The company has other tests in the pipeline, including for early detection of Lyme disease.

2019: Biotech
headquarters: Lexington, Massachusetts
T2 Biosystems On The Web